| The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation P Garnero, M Ferreras, MA Karsdal, R Nicamhlaoibh, J Risteli, O Borel, ... Journal of bone and Mineral Research 18 (5), 859-867, 2003 | 497 | 2003 |
| Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use VB Kraus, FJ Blanco, M Englund, MA Karsdal, LS Lohmander Osteoarthritis and cartilage 23 (8), 1233-1241, 2015 | 396 | 2015 |
| Republished: Value of biomarkers in osteoarthritis: current status and perspectives M Lotz, J Martel-Pelletier, C Christiansen, ML Brandi, O Bruyère, ... Postgraduate medical journal 90 (1061), 171-178, 2014 | 350 | 2014 |
| Local communication on and within bone controls bone remodeling K Henriksen, AV Neutzsky-Wulff, LF Bonewald, MA Karsdal Bone 44 (6), 1026-1033, 2009 | 322 | 2009 |
| Matrix metalloproteinase-dependent activation of latent transforming growth factor-β controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis MA Karsdal, L Larsen, MT Engsig, H Lou, M Ferreras, A Lochter, ... Journal of Biological Chemistry 277 (46), 44061-44067, 2002 | 279 | 2002 |
| Proteinases in bone resorption: obvious and less obvious roles JM Delaissé, MT Engsig, V Everts, M del Carmen Ovejero, M Ferreras, ... Clinica Chimica Acta 291 (2), 223-234, 2000 | 257 | 2000 |
| Are nonresorbing osteoclasts sources of bone anabolic activity? MA Karsdal, TJ Martin, J Bollerslev, C Christiansen, K Henriksen Journal of bone and mineral research 22 (4), 487-494, 2007 | 256 | 2007 |
| The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? F Genovese, AA Manresa, DJ Leeming, MA Karsdal, P Boor Fibrogenesis & tissue repair 7 (1), 1-14, 2014 | 255 | 2014 |
| The future of blood-based biomarkers for Alzheimer's disease K Henriksen, SE O’Bryant, H Hampel, JQ Trojanowski, TJ Montine, ... Alzheimer's & Dementia 10 (1), 115-131, 2014 | 252 | 2014 |
| Should subchondral bone turnover be targeted when treating osteoarthritis? MA Karsdal, DJ Leeming, EB Dam, K Henriksen, P Alexandersen, ... Osteoarthritis and cartilage 16 (6), 638-646, 2008 | 246 | 2008 |
| Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study RG Jenkins, JK Simpson, G Saini, JH Bentley, AM Russell, R Braybrooke, ... The lancet Respiratory medicine 3 (6), 462-472, 2015 | 224 | 2015 |
| Extracellular matrix remodeling: the common denominator in connective tissue diseases possibilities for evaluation and current understanding of the matrix as more than a … MA Karsdal, MJ Nielsen, JM Sand, K Henriksen, F Genovese, ... Assay and drug development technologies 11 (2), 70-92, 2013 | 222 | 2013 |
| Osteoclast activity and subtypes as a function of physiology and pathology—implications for future treatments of osteoporosis K Henriksen, J Bollerslev, V Everts, MA Karsdal Endocrine reviews 32 (1), 31-63, 2011 | 212 | 2011 |
| The disease modifying osteoarthritis drug (DMOAD): is it in the horizon? P Qvist, AC Bay-Jensen, C Christiansen, EB Dam, P Pastoureau, ... Pharmacological research 58 (1), 1-7, 2008 | 197 | 2008 |
| Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity MA Karsdal, SH Madsen, C Christiansen, K Henriksen, AJ Fosang, ... Arthritis research & therapy 10 (3), 1-12, 2008 | 195 | 2008 |
| Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future MA Karsdal, M Michaelis, C Ladel, AS Siebuhr, AR Bihlet, JR Andersen, ... Osteoarthritis and cartilage 24 (12), 2013-2021, 2016 | 193 | 2016 |
| Molecular serum markers of liver fibrosis T Liu, X Wang, MA Karsdal, DJ Leeming, F Genovese Biomarker insights 7, BMI. S10009, 2012 | 189 | 2012 |
| The good and the bad collagens of fibrosis–their role in signaling and organ function MA Karsdal, SH Nielsen, DJ Leeming, LL Langholm, MJ Nielsen, ... Advanced drug delivery reviews 121, 43-56, 2017 | 186 | 2017 |
| RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism K Henriksen, M Karsdal, JM Delaissé, MT Engsig Journal of Biological Chemistry 278 (49), 48745-48753, 2003 | 178 | 2003 |
| A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope … N Barascuk, SS Veidal, L Larsen, DV Larsen, MR Larsen, J Wang, ... Clinical biochemistry 43 (10-11), 899-904, 2010 | 177 | 2010 |
Anne Bay-JensenDirector, ImmunoScienceBekræftet mail på nordicbio.com
